L. Guggenhime Andrew's most recent trade in Vaxcyte Inc was a trade of 4,777 Common Stock done at an average price of $20.9 . Disclosure was reported to the exchange on April 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.93 per share. | 07 Apr 2025 | 4,777 | 131,950 | - | 20.9 | 99,983 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2025 | 4,777 | 121,115 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 75,991 | 75,991 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2025 | 22,761 | 132,252 | - | 0 | Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 72.10 per share. | 27 Feb 2025 | 3,809 | 127,173 | - | 72.1 | 274,629 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.02 per share. | 27 Feb 2025 | 1,270 | 130,982 | - | 73.0 | 92,735 | Common Stock |
| Caribou Biosciences Inc | Andrew L. Guggenhime | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 40,500 | 40,500 | - | - | Option to purchase Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Feb 2025 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Feb 2025 | 8,000 | 246,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 83.64 per share. | 18 Feb 2025 | 6,182 | 111,309 | - | 83.6 | 517,056 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 84.58 per share. | 18 Feb 2025 | 1,818 | 109,491 | - | 84.6 | 153,766 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 21 Jan 2025 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Jan 2025 | 8,000 | 254,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 86.08 per share. | 21 Jan 2025 | 5,318 | 112,173 | - | 86.1 | 457,795 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.25 per share. | 21 Jan 2025 | 1,999 | 110,174 | - | 87.2 | 174,407 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.70 per share. | 21 Jan 2025 | 683 | 109,491 | - | 87.7 | 59,899 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 8,000 | 262,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew Guggenhime L. | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Dec 2024 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | L. Guggenhime Andrew | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 88.70 per share. | 18 Dec 2024 | 3,373 | 112,928 | - | 88.7 | 299,188 | Common Stock |
| Vaxcyte Inc | Guggenhime Andrew L. | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 89.31 per share. | 18 Dec 2024 | 3,157 | 109,771 | - | 89.3 | 281,958 | Common Stock |
| Vaxcyte Inc | L. Guggenhime Andrew | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.26 per share. | 18 Dec 2024 | 1,190 | 116,301 | - | 87.3 | 103,835 | Common Stock |
| Vaxcyte Inc | Guggenhime Andrew L. | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 90.24 per share. | 18 Dec 2024 | 280 | 109,491 | - | 90.2 | 25,267 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Nov 2024 | 8,000 | 117,491 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2024 | 8,000 | 270,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 85.59 per share. | 18 Nov 2024 | 6,111 | 111,380 | - | 85.6 | 523,071 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 86.49 per share. | 18 Nov 2024 | 1,757 | 109,623 | - | 86.5 | 151,956 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 87.05 per share. | 18 Nov 2024 | 132 | 109,491 | - | 87.1 | 11,491 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 87,481 | 87,481 | - | - | Performance Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Nov 2024 | 35,661 | 35,661 | - | - | Performance Restricted Stock Units | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Oct 2024 | 19,108 | 125,892 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 20.93 per share. | 25 Oct 2024 | 19,108 | 109,491 | - | 20.9 | 399,930 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 115.26 per share. | 18 Oct 2024 | 36,114 | 96,269 | - | 115.3 | 4,162,608 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 14,000 | 278,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 14,000 | 132,383 | - | 5.4 | 74,900 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 12,000 | 292,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 12,000 | 118,383 | - | 5.4 | 64,200 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 8,000 | 98,383 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 8,000 | 304,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 8,000 | 312,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Oct 2024 | 8,000 | 106,383 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 116.19 per share. | 18 Oct 2024 | 5,886 | 90,383 | - | 116.2 | 683,900 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Sep 2024 | 8,000 | 98,383 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Sep 2024 | 8,000 | 320,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 115.60 per share. | 18 Sep 2024 | 5,485 | 92,898 | - | 115.6 | 634,052 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 116.29 per share. | 18 Sep 2024 | 1,686 | 91,212 | - | 116.3 | 196,065 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 117.53 per share. | 18 Sep 2024 | 829 | 90,383 | - | 117.5 | 97,433 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 110.15 per share. | 03 Sep 2024 | 6,337 | 90,383 | - | 110.2 | 698,021 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 19 Aug 2024 | 8,000 | 104,720 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2024 | 8,000 | 328,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 78.25 per share. | 19 Aug 2024 | 4,994 | 99,726 | - | 78.2 | 390,771 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 79.14 per share. | 19 Aug 2024 | 3,006 | 96,720 | - | 79.1 | 237,880 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Jul 2024 | 8,000 | 104,720 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jul 2024 | 8,000 | 336,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 80.12 per share. | 18 Jul 2024 | 3,095 | 101,625 | - | 80.1 | 247,956 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 81.06 per share. | 18 Jul 2024 | 2,500 | 99,125 | - | 81.1 | 202,638 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 82.32 per share. | 18 Jul 2024 | 1,479 | 97,646 | - | 82.3 | 121,747 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 83.14 per share. | 18 Jul 2024 | 926 | 96,720 | - | 83.1 | 76,985 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Jun 2024 | 8,000 | 104,720 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jun 2024 | 8,000 | 344,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 71.89 per share. | 18 Jun 2024 | 7,652 | 97,068 | - | 71.9 | 550,125 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 72.55 per share. | 18 Jun 2024 | 348 | 96,720 | - | 72.6 | 25,249 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 20 May 2024 | 8,000 | 103,679 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 May 2024 | 8,000 | 352,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 75.46 per share. | 20 May 2024 | 4,456 | 95,679 | - | 75.5 | 336,250 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 74.40 per share. | 20 May 2024 | 3,544 | 100,135 | - | 74.4 | 263,659 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Apr 2024 | 8,000 | 360,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Apr 2024 | 8,000 | 103,679 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 61.24 per share. | 18 Apr 2024 | 7,624 | 96,055 | - | 61.2 | 466,924 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 61.90 per share. | 18 Apr 2024 | 376 | 95,679 | - | 61.9 | 23,275 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Mar 2024 | 8,000 | 103,679 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Mar 2024 | 8,000 | 368,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 69.00 per share. | 18 Mar 2024 | 7,764 | 95,915 | - | 69.0 | 535,708 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 69.64 per share. | 18 Mar 2024 | 236 | 95,679 | - | 69.6 | 16,436 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 90,000 | 90,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Feb 2024 | 20,000 | 99,474 | - | 0 | Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 71.55 per share. | 29 Feb 2024 | 3,795 | 95,679 | - | 71.5 | 271,532 | Common Stock |
| Caribou Biosciences Inc | L. Andrew Guggenhime | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2024 | 39,500 | 39,500 | - | - | Option to purchase Common Stock | |
| Vaxcyte Inc | Guggenhime L. Andrew | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 20 Feb 2024 | 8,000 | 87,474 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Guggenhime Andrew L. | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Feb 2024 | 8,000 | 376,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | L. Guggenhime Andrew | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 74.08 per share. | 20 Feb 2024 | 4,909 | 82,565 | - | 74.1 | 363,659 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 75.17 per share. | 20 Feb 2024 | 2,751 | 79,814 | - | 75.2 | 206,801 | Common Stock |
| Vaxcyte Inc | L. Andrew Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 75.80 per share. | 20 Feb 2024 | 340 | 79,474 | - | 75.8 | 25,772 | Common Stock |
| Vaxcyte Inc | Guggenhime L. Andrew | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Jan 2024 | 8,000 | 87,474 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Guggenhime L. Andrew | PRESIDENT AND CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Jan 2024 | 8,000 | 384,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew Guggenhime L. | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 60.27 per share. | 18 Jan 2024 | 4,387 | 83,087 | - | 60.3 | 264,426 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 61.19 per share. | 18 Jan 2024 | 3,127 | 79,960 | - | 61.2 | 191,344 | Common Stock |
| Vaxcyte Inc | L. Andrew Guggenhime | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 61.88 per share. | 18 Jan 2024 | 463 | 79,497 | - | 61.9 | 28,651 | Common Stock |
| Vaxcyte Inc | Guggenhime L. Andrew | PRESIDENT AND CFO | Sale of securities on an exchange or to another person at price $ 63.35 per share. | 18 Jan 2024 | 23 | 79,474 | - | 63.3 | 1,457 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 18 Dec 2023 | 8,000 | 87,474 | - | 5.4 | 42,800 | Common Stock |
| Vaxcyte Inc | Andrew Guggenhime L. | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2023 | 8,000 | 392,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Guggenhime L. Andrew | President and CFO | Sale of securities on an exchange or to another person at price $ 60.17 per share. | 18 Dec 2023 | 7,883 | 79,591 | - | 60.2 | 474,304 | Common Stock |
| Vaxcyte Inc | Andrew Guggenhime L. | President and CFO | Sale of securities on an exchange or to another person at price $ 60.79 per share. | 18 Dec 2023 | 117 | 79,474 | - | 60.8 | 7,112 | Common Stock |
| Vaxcyte Inc | Guggenhime L. Andrew | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2023 | 14,000 | 400,827 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 14 Dec 2023 | 14,000 | 93,474 | - | 5.4 | 74,900 | Common Stock |
| Vaxcyte Inc | Andrew Guggenhime L. | President and CFO | Sale of securities on an exchange or to another person at price $ 60.22 per share. | 14 Dec 2023 | 14,000 | 79,474 | - | 60.2 | 843,080 | Common Stock |
| Vaxcyte Inc | Andrew L. Guggenhime | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 135,000 | 135,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 22,500 | 83,729 | - | 0 | Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | President and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.49 per share. | 01 Mar 2023 | 1,727 | 82,002 | - | 41.5 | 71,653 | Common Stock |
| Caribou Biosciences Inc | Andrew L. Guggenhime | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Feb 2023 | 21,500 | 21,500 | - | - | Option to purchase Common Stock | |
| Vaxcyte Inc | Andrew L. Guggenhime | President and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| Vaxcyte Inc | Andrew L. Guggenhime | President and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.35 per share. | 30 Dec 2022 | 23,691 | 61,229 | - | 5.4 | 126,747 | Common Stock |